Different options for the healthcare provider

my Prenatal

Singleton pregnancy

myPrenatal

Trisomy 21
Trisomy 18
Trisomy 13
+ Fetal sex +
Aneuploidies in sex chromosomes X and Y

Twin pregnancy

myPrenatal

Trisomy 21
Trisomy 18
Trisomy 13
+
Determination of Y chromosome presence

+

Singleton and Twin pregnancy

myPrenatal GenomeScreen

Duplications and deletions >7Mb (CNVs)

Aneuploidies in all chromosomes

The aneuploidies in all chromosomes in case of twin pregnancy and the analysis of the CNVs are limited to the autosomal chromosomes (not sexual).

CNVs (Copy Number Variants) larger than 7Mb are generally related to fetal anomalies and developmental delay.

- Veritas offers genetic counselling to the healthcare provider as part of the service provided.
- Moreover, if a high risk of CNVs is detected, Veritas includes a clinical interpretation of the result.
- The turnaround time is 5 working days since the sample arrives to the laboratory.



Veritas: *The Genome Company*

Leader in DNA sequencing and interpretation
Extensive experience in prenatal medicine
Experts in genetic counselling

Veritas was founded in 2018 by Dr. Luis Izquierdo, Dr. Vincenzo Cirigliano and Javier de Echevarría, who accumulate extensive experience in the field of genetics, diagnostics and biotechnology. Initially linked to Veritas Genetics, a company founded in 2014 by Prof. George Church, one of the pioneers in preventive medicine, Veritas was born with the aim of making genome sequencing and its clinical interpretation available to all citizens as a tool to prevent diseases and improve health and quality of life.

Since its inception, Veritas has led the activity and development in the markets in which it operates, with the goal of turning genomics into a daily instrument at the service of people's well-being.

In March 2022 Veritas announces that it will become part of LetsGetChecked, a global healthcare solutions company based in Dublin and New York that provides the tools to manage health from home, through direct access to diagnostic testing and virtual healthcare.

Veritas combines the most innovative new technology with clinical genetic expertise to offer physicians a comprehensive healthcare service during and after pregnancy.

my Newborn | The genetic screening test that allows personalizing the newborn's medical care from the first day of life.

Veritas
a LetsGetChecked company

(+34) 915 623 675 I info@veritasint.com
veritasint.com

MB.MP_EN_V1.5
08/07/2022



my Prenatal

The most comprehensive non-invasive prenatal test

Veritas
a LetsGetChecked company

veritasint.com

The genomic revolution of the NIPT

Veritas launches a new generation of Non-Invasive Prenatal Test (NIPT), maximizing the screening performance for common trisomies. The test also provides other analysis options to expand the screening including relevant alterations in the fetal genome.

A new generation of NIPT - myPrenatal GenomeScreen

Veritas offers a prenatal screening for the most common aneuploidies (21, 18, 13, X and Y), also offering the possibility to expand the screening to include:

- **Large deletions and duplications (CNVs) of more than 7 Mb**, alterations that may cause several fetal anomalies associated with delayed cognitive development.
- **Aneuploidies in all chromosomes**, associated with fetal loss and other structural alterations.

High accuracy analysis

myPrenatal provides excellent sensitivity and specificity values by using the **latest generation technology**. This provides great reliability to **reduce unnecessary invasive procedures.**

Prenatal experts

Veritas has an internationally **renowned team of experts in both genetic counselling and prenatal diagnosis** to support physicians with the assessment of results.

myPrenatal - Reliable results even with low fetal fraction

myPrenatal bioinformatic algorithm combines the **fetal DNA fraction and sequencing depth** to achieve **highly reliable results** in cases of low fetal fraction, reducing the rate of no-call results.

Available for singleton and twin pregnancies

It is possible to request the analysis of **common aneuploidies and the GenomeScreen option for both singleton and twin pregnancies.** The analysis of sex chromosomes aneuploidies can only be performed in singleton pregnancies.

NGS paired-end sequencing

NGS paired-end sequencing allows the discrimination of fetal and maternal cell-free DNA, **improving the fetal fraction assessment and bioinformatic analysis**, thus increasing test performance.

CE-IVD marked and performed in Europe

The test is performed in **our laboratories located in Europe** by an experienced team and is **CE-IVD marked.**





Performance

	Trisomy 21	Trisomy 18	Trisomy 13	Rare aneuploidies	Partial Del/dup
Sensitivity[1]	>99.9%	>99.9%	>99.9%	96.4%	74.1%
Specificity[1]	99.90%	99.90%	99.90%	99.80%	99.80%

Fetal sex concordance		
100% XX, XY, XXX, XXY	90.5% XO	91.7% XYY

myPrenatal – More accurate results

myPrenatal bioinformatic algorithm **assesses fetal fraction and sequencing depth** to deliver the best performance in all cases. In cases with low fetal fraction, results can be delivered with the same accuracy as in cases with a higher fetal fraction, if there is an appropriate sequencing depth. If the fetal fraction is high, the analysis requires a lower sequencing depth.

Other tests



Arbitrary fetal fraction limit of 4%, below this limit no results are delivered. This may occur in about 5% of cases[2]. The percentage of trisomies in samples with a fetal fraction <4% is significantly higher than in samples with higher fetal fractions[3].

myPrenatal



There is no established limit of fetal fraction. In cases with low fetal fraction with appropriate sequencing depth, it is possible to deliver reliable results, improving the sensitivity for detection of aneuploidies.

Bibliography:

1) Illumina. VeriSeq NIPT Solution v2 Package Insert. 2020.
2) Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372(17):1589-1597.
3) Revello R, Sarno L, Ispas A, et al. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound Obstet Gynecol. 2016;47(6):698-704.